Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Schizophrenia~* age 18-65 years~* necessity to establish new or change antipsychotic treatment due to unsatisfying results or side effects~* written informed consent~Exclusion Criteria (amongst others):~* Known or suspected hypersensitivity to olanzapine, quetiapine, aripiprazole, flupentixol or haloperidol~* Acute suicidal tendency~* Einwilligungsvorbehalt (BGB) or Unterbringung (PsychKG)~* Epilepsy~* Organic psychosis~* Parkinson Disease~* Dementia~* History of malignant neuroleptic syndrome~* QTc interval ≥ 0.5s / history of congenital QTc prolongation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- atypical antipsychotics (Type: EXPERIMENTAL): Olanzapine, Quetiapine, or Aripiprazole
- typical antipsychotics (Type: ACTIVE_COMPARATOR): Haloperidol or Flupentixol

Based on this trial design, predict the completion outcome and termination type (if applicable).